RNAi Therapeutics and Technology Market Top Companies Study -Alnylam, Novartis, Novo Nordisk, Regulus therapeutics, miRagen therapeutics.

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "RNAi Therapeutics and Technology Market by Type (Small interfering RNA (siRNA), MicroRNA (miRNA)), Application (Genetic Disorders, Oncology, Neurodegenerative Disorders, Infectious Diseases, Renal Diseases, Others), Route of Administration (Intradermal Injections, Pulmonary Delivery, Intravenous Injections), By Region, Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the RNAi Therapeutics and Technology Market is valued at US$ 1.49 Bn in 2023, and it is expected to reach US$ 5.02 Bn by 2031, with a CAGR of 16.6% during the forecast period of 2024-2031.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2508

RNA interference (RNAi) is an advanced biological process intrinsic to cells, complexly organizing gene expression through precise sequence-directed silencing. Leveraging this mechanism, RNAi therapeutics have emerged as a pioneering drug class, harnessing genes inherent in RNAi properties to regulate cellular expression systems naturally. Their potential to treat a diverse range of conditions, from metabolic and chronic diseases to cancer, has propelled RNAi therapeutics into the spotlight of medical research and innovation.

RNA interference (RNAi) therapeutics, leveraging the natural cellular process of gene silencing, promise a revolutionary approach to treating various diseases. With applications spanning metabolic disorders, chronic illnesses, and cancer, these therapeutics are categorised into diverse types. Antisense oligonucleotides, small interfering RNA (siRNA), and microRNAs (miRNA) each offer unique mechanisms to target specific genes, modulate gene expression, and regulate protein translation. RNAi therapeutics hold potential in disease treatment, gene regulation, editing, and silencing, offering precision in addressing conditions with challenging pathological origins.

List of Prominent Players in the RNAi Therapeutics and Technology:
• Alnylam Pharmaceuticals, Inc. (U.S.)
• Arbutus Biopharma Corporation
• Arrowhead Pharmaceuticals, Inc.
• Benitec Biopharma
• Dicerna Pharmaceuticals (Novo Nordisk A/S)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Glaxosmithkline Plc.
• Ionis Pharmaceuticals (U.S.)
• Moderna, Inc.
• Olix Pharmaceuticals, Inc.
• Quark Software Inc. (U.S.)
• Rexahn Pharmaceuticals, Inc.
• Sanofi
• Silence Therapeutics
• Thermo Fisher Scientific Inc.

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-02

Market Dynamics:
Drivers:
The escalating prevalence of chronic diseases globally, including cardiovascular ailments, cancer, diabetes, tuberculosis (TB), AIDS, and more, is poised to propel the growth of the global RNAi technology market in the foreseeable future. RNA-based therapeutics hold considerable promise in treating a spectrum of chronic diseases, as well as rare and genetic disorders. According to the World Health Organization (WHO), cardiovascular diseases claim a staggering 17.9 million non-communicable disease (NCD) deaths annually, followed by cancer, responsible for 9.3 million deaths, chronic respiratory diseases with 4.1 million, and diabetes with 2.0 million. The urgency to explore innovative treatments becomes paramount considering these statistics. The cancer diagnosis and treatment landscape is witnessing a transformative shift in integrating RNAi techniques into personalized medicine and molecular diagnostics. The advent of high-throughput methodologies for identifying altered cellular molecules and metabolites facilitates the application of RNAi techniques in diverse cancer diagnostic and therapeutic strategies, heralding a new era in precision medicine.

Challenges:
Challenges persist in the RNAi therapeutics and technology market, notably in delivery methods, where introducing RNA molecules to specific cells can provoke immune responses, limiting efficacy. One of the key barriers is exogenous RNA's intrinsic vulnerability to rapid disintegration by ubiquitous RNases found in both the environment and tissues. Additionally, effectively delivering negatively charged RNA molecules across the hydrophobic cytoplasmic membrane of target cells remains a critical challenge. Large-scale production poses another hurdle for companies, requiring innovative solutions to streamline manufacturing processes. Additionally, the potent immunogenicity of exogenous RNA poses a significant hindrance, leading to cell toxicity and impeding the translation of RNA into therapeutic proteins.

Regional Trends:
North America, particularly the United States, stands as the leading region in advancing RNAi therapeutics, driven by several key factors. The increasing prevalence of chronic diseases such as cancer, cardiovascular disorders, and neurodegenerative diseases in North America, where about 40% of American adults have multiple chronic conditions, underscores the demand for innovative treatments like RNAi therapeutics. This demand is further fueled by significant pharmaceutical investments, particularly in the US, propelling the development and adoption of RNAi-based therapies. The gene editing sector has attracted substantial investments from government agencies, venture capitalists, and private entities, bolstering momentum in the US. Moreover, North America benefits from a supportive regulatory environment, with well-established healthcare systems and agencies like the FDA facilitating the approval and adoption of novel therapies, including RNAi therapeutics.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2508

Recent Developments:
• In April 2024, Medison Pharma and Alnylam Pharmaceuticals, Inc. expanded their partnership to include selected markets in LATAM, APAC, and additional international markets, in addition to Central & Eastern Europe and Israel. This collaboration will allow companies to expand their footprint and provide the advantages of Alnylam's innovative RNAi treatments to patients in more APAC and LATAM regions.
• In November 2021, Arrowhead Pharmaceuticals linked an exclusive license deal with GlaxoSmithKline (GSK) for their experimental RNA interference (RNAi) therapeutic, ARO-HSD. GSK will lead the development and commercialization of ARO-HSD for treating nonalcoholic steatohepatitis (NASH). ARO-HSD targets HSD17B13 and holds promise as a therapy for both alcohol-related and nonalcohol-associated liver diseases, including NASH.

Segmentation of RNAi Therapeutics and Technology Market-
By Type
• Small interfering RNA (siRNA)
• MicroRNA (miRNA)
By Application
• Genetic Disorders
• Oncology
• Neurodegenerative Disorders
• Infectious Diseases
• Renal Diseases
• Others
By Route of Administration
• Intradermal Injections
• Pulmonary Delivery
• Intravenous Injections
By End-User
• Diagnostic Laboratories
• Research and Academic Laboratories
• Hospitals
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.